Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Functional dyspepsia. Current treatment recommendations

Gerald Holtmann1, Nicholas J Talley2

  • 1Division of Gastroenterology, University of Essen, Essen, Germany.

Drugs
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Challenges of Performing Controlled Trials of Diet Therapies in Gastroenterology.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.

The Medical journal of Australia·2026
Same author

Impact of bariatric surgery on alcohol-use disorder and alcohol-related liver disease: A retrospective study.

Addiction (Abingdon, England)·2026
Same author

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth (SIBO).

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior.

Neurogastroenterology and motility·2026
Same author

Sociocultural Aspects of the Pathophysiology, Clinical Presentation, and Management of Disorders of Gut-Brain Interaction.

Gastroenterology·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Functional dyspepsia affects 25% of people, causing upper abdominal pain without a clear cause. Current drug treatments offer some relief, but optimal therapy remains a trial-and-error process.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Functional dyspepsia (FD) affects up to 25% of the population, characterized by upper abdominal pain without structural or biochemical abnormalities.
  • Pathophysiological mechanisms, such as delayed gastric emptying, are implicated but not fully understood in FD.
  • Current drug treatments aim to modify presumed pathophysiological pathways.

Purpose of the Study:

  • To review the efficacy of current drug treatments for functional dyspepsia.
  • To highlight the limitations in understanding FD pathophysiology and the lack of clear treatment guidelines.
  • To emphasize the need for further research to personalize FD therapy.

Main Methods:

  • Review of existing literature on drug treatments for functional dyspepsia.
  • Analysis of placebo response rates and drug efficacy compared to placebo.

Related Experiment Videos

  • Discussion of proposed symptom-based treatment approaches and treatment duration.

    • Main Results:

    • Prokinetics, acid-suppressing agents, and bismuth compounds show statistically significant symptom reduction compared to placebo.
    • Antacids lack demonstrated efficacy over placebo in controlled studies; sucralfate's efficacy is uncertain.
    • Placebo response rates in FD trials are high, approaching 60%.

    Conclusions:

    • While some drugs offer benefits, rational guidelines for selecting treatments for individual functional dyspepsia patients are lacking.
    • Optimal treatment duration for long-lasting symptom relief is not well-defined.
    • Further research into the pathophysiology of FD is crucial for developing targeted therapies.